Table 2 Prognostic evaluation of clinical and histopatological characteristics – Overall Survival.

From: Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)

 

HR

Lower 95% HR

Upper 95% HR

P-value

Univariate

KRAS-LCS6 (TT vs TG/GG)

0.97

0.64

1.47

0.875

Age at diagnosis

1.02

1.00

1.03

0.058

Treatment arm (docetaxel vs erlotinib)

0.73

0.53

1.01

0.060

Sex (F vs M)

0.68

0.47

0.97

0.035

Smoking (smoking and ex vs not smoking)

1.23

0.83

1.81

0.297

Tumour grade

1.19

0.86

1.64

0.292

Tumour stage (IIIBw/IV vs III vs I/II)

1.19

0.95

1.49

0.126

ECOG-PS (2 vs. 1 vs. 0)

2.14

1.60

2.85

<.0001

Histotype (squamous vs others)

1.15

0.78

1.70

0.467

KRAS (mut vs wt)

1.36

0.94

1.96

0.106

Multivariate

KRAS-LCS6 (TT vs TG/GG)

0.82

0.54

1.26

0.373

Treatment arm (docetaxel vs erlotinib)

0.73

0.53

1.01

0.060

ECOG-PS (2 vs. 1 vs. 0)

2.17

1.62

2.91

<.0001

Back to article page